Compare Oxford Lane Capital Corp (OXLC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs TG Therapeutics Inc — how do they compare? Oxford Lane Capital Corp trades at $9.64 (market cap $942.56M), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 9× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 24.96% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| OXLC | TGTX | |
|---|---|---|
Market Cap | $942.56M | $8.53B |
Sector | Financials | Health |
52-Week High | $17.73 | $59.06 |
52-Week Low | $8.15 | $26.94 |
Dividend Yield | 24.96% | — |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $9.61, down 0.52% on the day, with a bullish technical signal supported by moving averages but mixed earnings performance. Recent quarters show significant misses versus expectations, including a large loss in Q1 2026, though the company maintains a steady dividend payout. Net income margin is exceptionally high at 100.85% for 2026, but this follows negative revenue, while 2025 showed positive net income of $48.46M. The P/B ratio of 0.91 suggests the stock trades below book value.
Outlook is cautious due to volatile earnings and high yield sustainability concerns, with analyst sentiment split evenly between buy and sell ratings. Key risks include earnings instability and reliance on financing cash flow, but the discount to book value and consistent dividends may appeal to income-focused investors amid bullish technical trends.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
